Lv1
82 积分 2025-08-20 加入
Excalipoint’s trispecific T cell engagers for solid tumors
2个月前
已关闭
Abstract 3510: A 2+1 format MUC16 targeting T cell engager induces MUC16-dependent T cell activity and superior anti-tumor efficacy
5个月前
已完结
Engineering CD3/CD137 Dual Specificity into a DLL3-Targeted T-Cell Engager Enhances T-Cell Infiltration and Efficacy against Small-Cell Lung Cancer
7个月前
已完结
Reducing affinity as a strategy to boost immunomodulatory antibody agonism
7个月前
已完结
Cathepsin B: The dawn of tumor therapy
7个月前
已完结
A recombinant polypeptide extends the in vivo half-life of peptides and proteins in a tunable manner
8个月前
已完结
IMT030122, A novel engineered EpCAM/CD3/4-1BB tri-specific antibody, enhances T-cell recruitment and demonstrates anti-tumor activity in mouse models of colorectal cancer
8个月前
已完结
A next generation mathematical model for the in vitro to clinical translation of T-cell engagers
9个月前
已完结
Treatment of metastatic renal cell carcinoma (mRCC) with CAIX CAR-engineered T-cells–a completed study overview
9个月前
已完结
皖公网安备34019202002308
